[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"schistosomiasis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:schistosomiasis":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,52,89,110,131,227,258,283],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":27,"conditions":28,"keywords":33,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100650974","different-treatment-frequencies-for-hepatic-fibrosis-due-to-schistosomiasis-an-rct-100650974",false,"NCT07754617","Different Treatment Frequencies for Hepatic Fibrosis Due to Schistosomiasis","An RCT to Evaluate Different Treatment Approaches to Mitigate the Progression of Schistosomiasis Related Hepatic Fibrosis","SchiFT","Inclusion Criteria:\n\n1. S. mansoni infection as determined by urine Circulating Cathodic Antigen (CCA)\n2. Otherwise healthy as determined by history and physical examination conducted by the study clinician\n3. Not Pregnant\n4. Age 15-40 years\n5. Consent for individuals 18 years of age and older, and parental consent and adolescent assent for participants ages 15-17 years.\n6. The presence of hepatic fibrosis due to S. mansoni (Niamey protocol grade C-F) and compensated (without late-stage portal hypertension) after ruling out other causes of hepatic fibrosis as below.\n\nExclusion Criteria:\n\n1. . History of upper gastrointestinal bleeding\n2. Hepatic fibrosis that is not deemed to be due to schistosomiasis based on ultrasound and hepatitis serologies. For example, alcoholic cirrhosis or presence of chronic Hepatitis B or C by point of care test\n3. Known neurocysticercosis or ocular cysticercosis","ALL","15 Years","40 Years",{"count":21,"type":22},600,"ESTIMATED","INTERVENTIONAL",[25,26],"PHASE2","PHASE3","The goal of this clinical trial is to learn if treating individuals living in Uganda who have liver fibrosis (scarring) due to schistosomiasis would benefit from more frequent treatment with drug praziquantel. This drug is already approved to treat schistosomiasis and is used globally. The study will include individuals who have schistosomiasis and some degree of liver fibrosis. The main questions it aims to answer are:\n\n1. Does treating participants three times per year as compared to once per year as currently recommended improve the likelihood the hepatic fibrosis will improve over three years.\n2. Does treating participants three times per year as compared to once per year as currently recommended decrease the risk they have for bleeding due to portal hypertension over three years.\n3. Is there a blood test that can tell us which individuals will experience worsening liver fibrosis before this happens.\n\nParticipants will:\n\nBe screened for schistosomiasis using a urine test If participants have schistosomiasis they will undergo other screening procedures including a liver ultrasound, blood tests, and a physical exam if they have both schistosomiasis and liver (fibrosis) they will be invited to participate in the trial\n\nIf they are in the trial they will:\n\nTake the drug praziquantel once per year or three times per year based on randomization for three years Have a liver ultrasound and blood samples for markers of liver fibrosis once per year Provide a urine sample to test for schistosomiasis each year",[29,30,31,32],"Schistosomiasis","Schistosoma Mansoni","Liver Fibrosis","Portal Hypertension",[34,35,36,37,38],"schistosomiasis","schistosome mansoni","hepatic fibrosis","liver fibrosis","portal hypertension","NOT_YET_RECRUITING","2026-08-07",{"date":42,"type":43},"2026-08-12","ACTUAL",{"date":45,"type":22},"2026-11",{"date":47,"type":22},"2029-11",{"name":49,"class":50},"Rhode Island Hospital","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":60,"sex":17,"minAge":61,"maxAge":4,"enrollmentInfo":62,"targetDuration":4,"studyType":23,"phases":64,"briefSummary":66,"conditions":67,"keywords":71,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":51},"100647299","expanding-access-to-preventive-chemotherapy-among-mobile-and-migrant-populations-100647299","NCT07707817","Expanding Access to Preventive Chemotherapy Among Mobile and Migrant Populations","A Community Mapping and Participatory Research Protocol for Expanding Access to Preventive Chemotherapy Among Mobile and Migrant Populations Through Social and Occupational Networks in Nigeria: MISSION Nigeria","MISSION","Inclusion Criteria:\n\nParticipants will be eligible for inclusion if they:\n\n1. Are children aged 5-14 years or adult heads of households residing in households identified as belonging to mobile or migrant populations.\n2. Reside permanently or semi-permanently within the study communities\n3. Have missed one or more previous rounds of onchocerciasis and\u002For lymphatic filariasis MDA.\n4. Are willing to provide the required biological specimens and participate in interviews, surveys, and participatory workshops or discussions as required by the study protocol.\n5. Provide informed consent or assent with parental\u002Fguardian consent where applicable for minors.\n\nExclusion Criteria:\n\nParticipants will be excluded if they:\n\n1. Are temporary visitors without meaningful residence in the study communities.\n2. Do not belong to the identified mobile or migrant populations targeted by the study.\n3. Are unable or unwilling to provide the required biological specimens or participate in study procedures.\n4. Decline informed consent or assent, or whose parent or guardian declines consent for participation.\n5. Are severely ill or have medical conditions that, in the opinion of study personnel, would make participation unsafe or inappropriate.",true,"5 Years",{"count":63,"type":22},5760,[65],"NA","Neglected Tropical Diseases (NTDs) are among the most common groups of diseases affecting over one billion people globally and are disproportionately concentrated in remote, underserved, and marginalized communities. Efforts toward NTD elimination have largely relied on preventive chemotherapy (PC), large-scale distribution of free, safe, and effective medicines to at-risk populations. One major challenge threatening elimination efforts is the poor participation of mobile and migrant populations (MMPs) in treatment programs. Despite this gap, few studies have explored strategies to improve access among these underserved populations.\n\nThis study aims to determine the burden of NTDs among MMPs and explore strategies for expanding access to preventive chemotherapy through social and occupational networks using community mapping and participatory action research approaches in Nigeria.\n\nThis project is a multi-site implementation research study involving 15 communities across three Nigerian states-Taraba, Akwa Ibom, and Ondo-representing pastoralist, fishing, and agrarian settings, respectively. The study comprises four phases. The first two formative phases will assess the baseline burden of NTDs and coverage of preventive chemotherapy interventions using community surveys, parasitological and serological assessments, mapping, and participatory workshops to identify migration patterns, anchor points, and social and occupational networks that could support expansion of PC. The third phase will use participatory approaches to co-construct context-specific strategies for expanding access to preventive chemotherapy among MMPs. In the fourth phase, the co-developed strategies will be implemented and evaluated for impact using established implementation research frameworks and mixed methods approaches.\n\nThrough this project, investigators will develop and evaluate a novel strategy for expanding access to PC among MMPs. The study will generate evidence on the feasibility, acceptability, reach, and sustainability of the proposed approach and is expected to inform adaptable implementation models for inclusive NTD programming in Nigeria and similar endemic settings.",[68,29,69,70],"Onchocerciasis (River Blindness)","Soil Transmitted Helminth (STH) Infections","Lymphatic Filariasis",[72,73,74,75,76,77,78],"Neglected Tropical Diseases","Mobile and Migrant populations","Participatory Research","Implementation Science","Nigeria","Mass Drug Administration","Mass Administration of Medicines","RECRUITING","2026-07-14",{"date":82,"type":43},"2026-07-16",{"date":84,"type":43},"2026-07-01",{"date":86,"type":22},"2027-11-30",{"name":88,"class":50},"Uwemedimo Friday Ekpo",{"id":90,"slug":91,"hasResults":11,"nctId":92,"briefTitle":93,"officialTitle":93,"acronym":94,"eligibilityCriteria":95,"healthyVolunteers":11,"sex":17,"minAge":96,"maxAge":4,"enrollmentInfo":97,"targetDuration":4,"studyType":23,"phases":99,"briefSummary":100,"conditions":101,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":51},"100647446","assessment-of-right-ventricular-pulmonary-arterial-coupling-in-schistosomiasis-associated-pulmonary-arterial-hypertension-100647446","NCT07707193","Assessment of Right Ventricular-Pulmonary Arterial Coupling in Schistosomiasis-Associated Pulmonary Arterial Hypertension","Sch-PAH RV-PA","Inclusion Criteria:\n\n* All patients above 18 year diagnosed with schistozomiasis through history of exposure , serology , positive stool antigens ,Symmers' periportal fibrosis (the \"clay pipe-stem\" appearance) or Splenomegaly and suspected pulmonary hypertension through Probability Score\" approach based on the 2022 ESC\u002FERS\n\nExclusion Criteria:\n\n* All patients below 18 years old.\n* Left ventricular systolic or diastolic dysfunction.\n* Significant left-sided valvular heart disease.\n* severe chronic lung disease such as, Chronic obstructive pulmonary disease (COPD) ---- GOLD 4 and severe Interstitial lung disease (ILD).\n* Chronic Thromboembolic Pulmonary Hypertension.\n* Congenital heart diseases.\n* Severe hepatic or renal impairment unrelated to schistosomiasis.\n* Hemodynamically unstable patients.\n* Poor echocardiographic window preventing adequate RV assessment.\n* Active infection or acute systemic illness.\n* Refusal to participate in the study.\n* Significant arrhythmias affecting hemodynamic assessment (e.g., uncontrolled atrial fibrillation).\n* Previous heart or lung transplantation.\n* Pregnancy.","18 Years",{"count":98,"type":22},50,[65],"Pulmonary Arterial Hypertension is a progressive and potentially fatal cardiopulmonary disorder characterized by remodeling of the pulmonary vasculature, progressive elevation of pulmonary vascular resistance (PVR), and eventual right ventricular (RV) failure.\n\nAccording to the 2022 European Society of Cardiology\u002FEuropean Respiratory Society (ESC\u002FERS) guidelines, pulmonary hypertension is currently defined hemodynamically by a mean pulmonary arterial pressure (mPAP) \\>20 mmHg measured by right heart catheterization, while pulmonary arterial hypertension is additionally characterized by pulmonary arterial wedge pressure (PAWP) ≤15 mmHg and PVR \\>2 Wood units.\n\nSchistosomiasis-associated pulmonary arterial hypertension (Sch-PAH) is classified within Group 1 PAH and represents one of the most important causes of PAH in endemic regions, particularly in developing countries such as Egypt and Brazil.\n\nSchistosomiasis is considered the second most prevalent parasitic disease worldwide after malaria, affecting more than 200 million individuals globally. Chronic hepatosplenic schistosomiasis may lead to porto-systemic shunting, allowing parasite eggs to embolize into the pulmonary circulation, triggering chronic inflammation, endothelial dysfunction, and pulmonary vascular remodeling.\n\nThe pathological changes observed in Sch-PAH resemble those seen in idiopathic PAH, including medial hypertrophy, intimal fibrosis, and plexiform lesions. However, several studies suggest that patients with Sch-PAH may exhibit better long-term survival compared with idiopathic PAH despite comparable pulmonary hemodynamic impairment.\n\nThe mechanisms underlying this relatively favorable prognosis remain incompletely understood.\n\nRight ventricular adaptation to increased afterload is currently recognized as one of the principal determinants of prognosis in PAH.",[29],"2026-07-13",{"date":82,"type":43},{"date":105,"type":22},"2026-07",{"date":107,"type":22},"2027-07-01",{"name":109,"class":50},"Sohag University",{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":4,"eligibilityCriteria":116,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":117,"targetDuration":4,"studyType":119,"phases":4,"briefSummary":120,"conditions":121,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":4},"100630018","prevalence-and-molecular-identification-of-human-schistosomiasis-100630018","NCT07482215","Prevalence and Molecular Identification of Human Schistosomiasis","Prevalence and Molecular Identification of Human Schistosomiasis With Assessment of Associated Epidemiological Risk Factors in Assiut Governorate, Egypt","Inclusion Criteria:\n\n* Patients aged ≥ 5 years of both sexes attending Assiut Governorate hospitals during the study period.\n* Patients clinically suspected of having schistosomiasis (urinary and\u002For intestinal) or referred for parasitological examination.\n* Individuals (or guardians, in case of minors) who provide written informed consent.\n* Patients willing to provide the required biological samples (urine and\u002For stool).\n\nExclusion Criteria:\n\n* Patients Received praziquantel within the last 3 months before sample collection\n* Patients with incomplete clinical or epidemiological data.\n* Patients refusing participation or sample collection.\n* Improperly collected, contaminated, or insufficient samples.\n* Patients suffering from severe comorbid conditions that may interfere with the interpretation of results (e.g., advanced hepatic or renal failure).\n* children with congenital urinary or intestinal anomalies.",{"count":118,"type":22},359,"OBSERVATIONAL","Schistosomiasis remains one of the most important parasitic diseases of public health concern, particularly in developing countries including Egypt. It is caused by a trematode worm (blood flukes) of the genus Schistosoma",[29],"2026-03-16",{"date":124,"type":43},"2026-03-19",{"date":126,"type":22},"2026-05",{"date":128,"type":22},"2027-12",{"name":130,"class":50},"Assiut University",{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":135,"acronym":136,"eligibilityCriteria":137,"healthyVolunteers":60,"sex":17,"minAge":138,"maxAge":139,"enrollmentInfo":140,"targetDuration":4,"studyType":119,"phases":4,"briefSummary":142,"conditions":143,"keywords":200,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":219,"startDateStruct":221,"completionDateStruct":223,"leadSponsor":225,"locationsCount":51},"100620537","risk-assessment-of-community-spread-of-multiple-endemic-infectious-diseases-in-a-one-health-perspective-100620537","NCT07358910","Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective","RACSMEI","Inclusion Criteria:\n\n* Residency in the village for more than 6 months;\n* Age between 2 and 75 years old at the time of inclusion;\n* For adults: provision of written consent;\n* For children aged 2-17 years: written parental consent form, verbal assent from children aged 13-17 years;\n\nExclusion Criteria:\n\n* Unable to understand or consent;\n* Under guardianship or deprived of liberty;\n* Medical conditions that impede survey participation;\n* Refusal to participate in the study.","2 Years","75 Years",{"count":141,"type":22},10000,"RACSMEI addresses the high burden of infectious diseases in low- and middle-income countries, including Cambodia, where limited surveillance and laboratory capacity often obscure etiologies and transmission dynamics. This knowledge gap hinders the design of effective prevention and control strategies.\n\nRACSMEI will improve understanding across multiple pathogens using a multidisciplinary One Health approach. We will answer key questions on burden, ecology, transmission and population immune status to inform targeted and culturally appropriate interventions. The project combines a nationally representative One Health survey, social-science methods, and multiplex, diverse diagnostics to efficiently test for 57 priority pathogens, including zoonotic and vector-borne agents, vaccine-preventable and elimination-targeted diseases, enteric, respiratory, and environmentally transmitted pathogens and selected neglected tropical diseases and parasites relevant to Cambodia.\n\nMathematical modelling will reconstruct and forecast transmission dynamics and assess the potential impact of future public-health strategies. By integrating intersectoral data and innovative methods, RACSMEI will generate actionable evidence for public-health authorities, support precision One Health interventions, and help reduce disease burden in affected communities. The project also aims to ensure the transferability of methods and insights to other countries facing similar challenges.",[144,145,146,147,148,149,150,151,152,153,154,155,156,157,158,159,160,161,162,163,164,165,166,167,168,169,170,171,172,173,174,175,176,177,178,179,180,181,182,183,184,185,186,187,188,70,189,190,191,192,193,194,195,196,197,29,198,199],"Dengue","Chikungunya","Zika Virus Infection","Japanese Encephalitis","West Nile Virus","Tick-borne Encephalitis (TBE)","Severe Fever With Thrombocytopenia Syndrome","Nipah Virus Infection","Hantavirus Infections","Hepatitis E","Brucellosis","Q Fever","Leptospirosis","Melioidosis","Influenza A and B","Malaria","Yellow Fever","Mayaro Fever","Usutu Virus Infection","Oropouche Fever","Rift Valley Fever","Arenavirus Infections","Measles","Mumps","Rubella","Human Papilloma Virus (HPV)","Rotavirus Disease","Pertussis","Diphteria","Tetanus","Varicella","Hepatitis A","Norovirus Infections","Enterovirus","Adenovirus","Rhinovirus","Parvovirus","Respiratory Syncytial Virus (RSV)","Cytomegalovirus","Epstein Barr Virus","Salmonella Typhi","Vibrio Cholerae","Legionella Pneumophila Pneumonia","Mycoplasma","Chlamydia","Toxoplasma Gondii","Giardiasis","Entamoeba Histolytica","Leishmaniasis","Strongyloides Stercoralis Infection","Ascaris Lumbricoides","Trichuris Trichiura","Clonorchis Sinensis","Opisthorchis Viverrini","Streptococcus Pneumoniae","Meningitis",[201,202,203,204,205,206,207,208,209,210,211,212,213,214,215,216,217],"Infectious disease","One Health","Population-based survey","Nationally representative survey","Seroepidemiology","Multiplex serology","Seroprevalence","Vector-borne diseases","Zoonoses","Vaccine-preventable diseases","Neglected tropical diseases","Transmission dynamics","Force of infection","Mathematical modelling","Spatial epidemiology","Precision public health","Cambodia","2026-01-14",{"date":220,"type":43},"2026-01-22",{"date":222,"type":43},"2025-12-18",{"date":224,"type":22},"2027-09-30",{"name":226,"class":50},"Institut Pasteur du Cambodge",{"id":228,"slug":229,"hasResults":11,"nctId":230,"briefTitle":231,"officialTitle":232,"acronym":233,"eligibilityCriteria":234,"healthyVolunteers":60,"sex":17,"minAge":235,"maxAge":236,"enrollmentInfo":237,"targetDuration":4,"studyType":119,"phases":4,"briefSummary":239,"conditions":240,"keywords":241,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":248,"lastUpdatePostDateStruct":249,"startDateStruct":251,"completionDateStruct":253,"leadSponsor":255,"locationsCount":257},"100569766","introduction-of-arpraziquantel-treatment-for-schistosomiasis-control-in-preschool-aged-children-in-endemic-areas-a-small-scale-public-health-intervention-study-100569766","NCT06698510","Introduction of Arpraziquantel Treatment for Schistosomiasis Control in Preschool-aged Children in Endemic Areas: A Small-scale Public Health Intervention Study","Arpraziquantel for Schistosomiasis Control in Preschool-aged Children in Endemic Areas in Kenya and Côte d'Ivoire: A Small-scale Public Health Intervention Study Arpraziquantel for Schistosomiasis Control in Preschool-aged Children in Endemic Areas in Uganda, With Special Consideration of Dose Determination Methods: a Small-scale Public Health Intervention Study in Hoima and Bugiri Districts","ADOPTpilot","* Living in the designated implementation area since at least 6 months\n* Aged between 24 - 59 months\n* Informed consent available\n* No acute or chronic illness and\u002For inability to take oral medication\n* No reported history of seizures\n* No known allergic response to praziquantel","24 Months","59 Months",{"count":238,"type":22},18500,"The proposed small-scale pilot studies are public health intervention studies implemented through established routine programs and services in the frame of the mass drug administration (MDA) campaigns in Côte d'Ivoire, Kenya and Uganda. In each country two most promising health intervention platforms were selected for pilot distribution of arpraziquantel 150mg (arPZQ).\n\nThe aim of the small-scale pilot study is to assess the performance of different platforms for distributing arPZQ, a child-friendly formulation of praziquantel, to the target population (i.e., preschool-aged children (PSAC)) currently missed out in schistosomiasis treatment campaigns.\n\nThe specific objectives of the pilot study are:\n\n* To assess the performance of different platforms for delivery of arPZQ to PSAC aged 24 to 59 months in terms of coverage, feasibility and acceptability\n* To determine social mobilization and training needs for effective delivery of arPZQ through different platforms\n\nPreventive chemotherapy with arPZQ will be offered systematically to eligible PSAC aged 2 to below 5 years of consenting caregivers resident in the study area and reached through the selected platforms. Adverse events during MDA with arPZQ will be documented and reported by using existing tools and established reporting pathways aligned with standard pharmacovigilance and safety guidelines of the national drug authorities. Based on routine program processes and forms, variables pertaining to drug logistics, training, drug distribution, passive pharmacovigilance and supervision will be collected in order to measure and generate real-world data related to feasibility, coverage and acceptability of selected platforms and strategies to inform future scale-up to district levels.\n\nAssessments will take place before (to capture social mobilization and training activities) during and after the drug distribution to document the implementation process and evaluate experiences made by the different stakeholders (e.g. children, parents, community members, health workers, programme staff).",[29],[34,242,243,244,245,246,247],"preschool-aged children","praziquantel","arpraziquantel","deworming","pediatric treatment","child health","2025-09-19",{"date":250,"type":43},"2025-09-24",{"date":252,"type":43},"2024-11-25",{"date":254,"type":22},"2026-03",{"name":256,"class":50},"Peter Steinmann",7,{"id":259,"slug":260,"hasResults":11,"nctId":261,"briefTitle":262,"officialTitle":263,"acronym":264,"eligibilityCriteria":265,"healthyVolunteers":11,"sex":17,"minAge":61,"maxAge":4,"enrollmentInfo":266,"targetDuration":4,"studyType":23,"phases":268,"briefSummary":269,"conditions":270,"keywords":271,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":274,"lastUpdatePostDateStruct":275,"startDateStruct":277,"completionDateStruct":279,"leadSponsor":281,"locationsCount":5},"100583206","assessment-of-infection-activity-in-travelers-and-migrants-diagnosed-with-chronic-schistosomiasis-100583206","NCT06873308","Assessment of Infection Activity in Travelers and Migrants Diagnosed With Chronic Schistosomiasis","Assessment of Infection Activity in Travelers and Migrants Diagnosed With Chronic Schistosomiasis: a Multicentric Prospective Cohort Study","SchistAct","Inclusion criteria\n\n1. diagnosis of chronic schistosomiasis (\\>3 months after last potential exposure) according to site-specific diagnostic practice\n2. signed informed consent (and assent for minors).\n\nExclusion criteria\n\n1. age below 5 years;\n2. exposure to praziquantel after the last potential exposure to schistosomes\n3. acute infection, i.e. likely infection \\\u003C3 months before presentation",{"count":267,"type":22},278,[65],"The primary objective of this clinical investigation is to determine the percentage of travelers and migrants diagnosed with chronic schistosomiasis according to site-specific diagnostic practice who have active infection at the time of evaluation (as assessed and classified by composite reference standards that integrate clinical, laboratory, and diagnostic features, such as microscopy, PCR (where available), POC-CCA (where available), and serum CAA results).\n\nAll subjects with chronic schistosomiasis according to site-specific diagnostic practice will have a standardized baseline clinical and laboratory evaluation at the time of evaluation that will include blood sampling for hematology, schistosome serology available at each site, and schistosome PCR where available; urine sampling for microscopy, determination of hematuria as an indirect marker of morbidity for schistosomiasis, and Schistosome PCR (where available), and urine strip testing POC-CCA (where available); and stool sampling for microscopy and PCR, where available, and fecal occult blood as indirect markers of schistosomiasis morbidity.\n\nComposite reference standards will be used to assess and classify the activity of the infection. Organ-specific ultrasound and other tests will be left to the physician's decision, but results will also be collected.\n\nSerum (at least 1 ml remaining from routine diagnostics) will be sent to LUMC, the Netherlands, where CAA will be determined with the UCP-LF CAA test designed for routine use.\n\nParticipants will be asked to sign an additional consent form, which is optional and not precluding enrollment in the study, to allow the remaining serum to be stored at LUMC for 15 years, to allow secondary research.",[29],[34,272,273],"chronic","diagnosis","2025-04-16",{"date":276,"type":43},"2025-04-20",{"date":278,"type":43},"2024-06-28",{"date":280,"type":22},"2027-01",{"name":282,"class":50},"IRCCS Sacro Cuore Don Calabria di Negrar",{"id":284,"slug":285,"hasResults":11,"nctId":286,"briefTitle":287,"officialTitle":287,"acronym":288,"eligibilityCriteria":289,"healthyVolunteers":11,"sex":290,"minAge":291,"maxAge":292,"enrollmentInfo":293,"targetDuration":4,"studyType":23,"phases":294,"briefSummary":295,"conditions":296,"keywords":298,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":304,"lastUpdatePostDateStruct":305,"startDateStruct":307,"completionDateStruct":308,"leadSponsor":310,"locationsCount":4},"100579764","female-genital-schistosomiasis-in-migrant-women-a-pilot-study-100579764","NCT06828536","Female Genital Schistosomiasis in Migrant Women: A Pilot Study","GynoBizh","Inclusion Criteria:\n\n* Women aged 25 to 65 years\n* Born in a schistosomiasis-endemic area in sub-Saharan Africa\n* With a positive serology by Schistosoma spp. Western Blot\n\nExclusion Criteria:\n\n* Refusal to participate in the study\n* Patient unable to provide consent\n* Patient under guardianship or trusteeship\n* Patient who is a virgin at the time of selection\n* Patient who is pregnant at the time of selection","FEMALE","25 Years","65 Years",{"count":98,"type":22},[65],"This pilot study, \"GynoBizh,\" investigates the frequency and clinical characteristics of female genital schistosomiasis (FGS) among migrant women from sub-Saharan Africa living in non-endemic countries. Schistosomiasis is a significant global parasitic disease, with a high seroprevalence in migrants. The study aims to assess the presence of genital lesions through gynecological examinations, colposcopy, and molecular tests, identifying diagnostic markers and associated health conditions. Fifty participants will be followed over a year to improve understanding and management of FGS in underserved populations.",[297,29],"Diagnostic",[299,300,301,302,303],"femal genital schistosomiasis","migrant women","colposcopy","Diagnostic pilot study","Schistosoma spp. PCR","2025-02-10",{"date":306,"type":43},"2025-02-14",{"date":304,"type":22},{"date":309,"type":22},"2026-08-10",{"name":311,"class":50},"Assistance Publique - Hôpitaux de Paris"]